Perspectives on cancer care in older patients in France.

France aging cancer geriatric assessment geriatric oncology global health health services older

Journal

Ecancermedicalscience
ISSN: 1754-6605
Titre abrégé: Ecancermedicalscience
Pays: England
ID NLM: 101392236

Informations de publication

Date de publication:
2020
Historique:
received: 03 06 2020
entrez: 21 10 2020
pubmed: 22 10 2020
medline: 22 10 2020
Statut: epublish

Résumé

In France, cancer is the leading cause of death. Its incidence is increasing due to the growing population and longer life expectancy. Although older adults represent most new cases, they remain underrepresented in clinical trials. Their prognosis is often worse due to delayed diagnosis and multimorbidities. Geriatric oncology has made great strides worldwide, highlighted by important studies implementing geriatric assessment in clinical research and supported by the successive national cancer plans. This paper reviews the most important actions taken in France during the last decade to improve the management of older patients with cancer.

Identifiants

pubmed: 33082853
doi: 10.3332/ecancer.2020.1103
pii: can-14-1103
pmc: PMC7532034
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

1103

Informations de copyright

© the authors; licensee ecancermedicalscience.

Déclaration de conflit d'intérêts

The authors state no conflicts of interest regarding this publication.

Références

J Geriatr Oncol. 2014 Jan;5(1):11-9
pubmed: 24484713
PLoS One. 2014 Dec 11;9(12):e115060
pubmed: 25503576
Int J Cancer. 2019 Jan 1;144(1):49-58
pubmed: 29978474
J Clin Oncol. 2007 May 10;25(14):1824-31
pubmed: 17488980
Ann Oncol. 2015 Feb;26(2):288-300
pubmed: 24936581
Eur J Cancer. 2018 Nov;103:61-68
pubmed: 30212804
Lancet Oncol. 2014 Jan;15(1):23-34
pubmed: 24314615
J Gerontol A Biol Sci Med Sci. 2008 Jul;63(7):724-30
pubmed: 18693227
Ann Oncol. 2006 Feb;17(2):211-6
pubmed: 16291586
Eur J Cancer. 2017 Sep;83:211-219
pubmed: 28750273

Auteurs

Mathilde Hauchecorne (M)

Senior Oncology Unit, Medical Oncology Department, Gustave Roussy Cancer Campus, Chevilly-Larue 94550, France.

Monica Pierro (M)

Medical Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France.

Etienne Brain (E)

Department of Medical Oncology, Institut Curie, Saint-Cloud 92210, France.

Michael Bringuier (M)

Department of Medical Oncology, Institut Curie, Saint-Cloud 92210, France.

Pierre Soubeyran (P)

Department of Medical Oncology, Institut Bergonié, Université de Bordeaux, Inserm U1218, 33076 Bordeaux Cedex, France.

Camille Chakiba (C)

Department of Medical Oncology, Institut Bergonié, Université de Bordeaux, Inserm U1218, 33076 Bordeaux Cedex, France.

Simone Mathoulin-Pelissier (S)

INSERM CIC1401, Institut Bergonie, Comprehensive Cancer Center, F-33000 Bordeaux, France.

Elena Paillaud (E)

APHP, Paris Cancer Institute CARPEM, Department of Geriatrics, European Georges Pompidou Hospital, Paris 75015, France.
Univ Paris Est Creteil, INSERM, IMRB, F-94010 Creteil, France.

Romain Geiss (R)

APHP, Paris Cancer Institute CARPEM, Department of Geriatrics, European Georges Pompidou Hospital, Paris 75015, France.

Benjamin Besse (B)

Medical Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France.

Loïc Mourey (L)

Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse 31059, France.

Hélène Vincent (H)

Senior Oncology Unit, Medical Oncology Department, Gustave Roussy Cancer Campus, Chevilly-Larue 94550, France.

Capucine Baldini (C)

Senior Oncology Unit, Medical Oncology Department, Gustave Roussy Cancer Campus, Chevilly-Larue 94550, France.
Drug Development Department, Gustave Roussy, Villejuif 94800, France.

Classifications MeSH